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Abstract 
 
Vibrio vulnificus is an etiological agent causing serious systemic infections in the 
immunocompromised humans or cultured eels. This species commonly produces a hemolytic 
toxin consisting of the cytolysin domain and the lectin-like domain. For hemolysis, the 5 
lectin-like domain specifically binds to cholesterol in the erythrocyte membrane, and to form 
a hollow oligomer, the toxin is subsequently assembled on the membrane. The cytolysin 
domain is essential for the process to form the oligomer. Three-dimensional structure model 
revealed that two domains connected linearly and the C-terminus was located near to the joint 
of the domains. Insertion of amino acid residues between two domains was found to cause 10 
inactivation of the toxin. In the C-terminus, deletion, substitution or addition of an amino acid 
residue also elicited reduction of the activity. However, the cholesterol-binding ability was 
not affected by the mutations. These results suggest that mutation of the C- or N-terminus of 
the lectin-like domain may result in blockage of the toxin assembly. 
 15 
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1. Introduction 
 
Vibrio vulnificus is a facultative anaerobic gram-negative bacterium inhabiting 
ubiquitously at estuarine and marine environments (Janda et al., 1988; Chakraborty et al., 
1997). However, this bacterium is an etiological agent causing fatal septicemia in humans by 5 
consumption of contaminated seafood, whereas most of the patients have underlying diseases 
such as hepatic cirrhosis, hepatitis or diabetes (Strom and Paranjpye, 2000; Miyoshi 2006). V. 
vulnificus also causes serious systemic infections called vibriosis in cultured eels (Tison et al., 
1982). This species commonly produces a hemolytic/cytolytic toxin termed V. vulnificus 
hemolysin (VVH) (Shinoda et al., 1985; Miyoshi et al., 1993), which has been reported to 10 
cause cytolysis of various eukaryotic cells, as well as erythrocytes (Yamanaka et al., 1990; 
Miyoshi et al., 1993; Kashimoto at al., 2010). For hemolysis, the toxin binds specifically to 
cholesterol and is subsequently assembled on the membrane to form an oligomer (Yamanaka 
et al., 1987; Kim and Kim, 2002). Although VVH is a single polypeptide consisting of 451 
amino acid residues (Yamamoto et al., 1990), it is divided into two functional domains, the 15 
cytolysin domain (Gln1 to Ala318) essential for the toxin assembly and the lectin-like domain 
(His319 to Leu451) mediating the toxin binding (Olson and Gouaux, 2005). Indeed, our recent 
study demonstrated that replacement of Thr438 in the lectin-like domain caused significant 
change of the affinity to cholesterol (Senoh et al., 2008). The VVH precursor is encoded in the 
vvhA gene (1416 bp), while it constitutes an operon with the vvhB gene (507 bp) (Yamamoto 20 
et al., 1990). Senoh et al. (2008) reported that the product of vvhB functioned as a chaperone 
to support the maturation of VVH. 
The overall three-dimensional structures of bacterial hemolytic/cytolytic toxins are 
considerably similar each other even though their primary structures are not fairly related 
(Tilley and Saibil, 2006; Iacovache et al., 2010). Vibrio cholerae, a human pathogen causing 25 
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cholera or enteric diseases, also produces a hemolytic toxin, of which amino acid sequence is 
17 % identical with VVH (Yamamoto et al., 1990). Based on the crystal structure of V. 
cholerae hemolysin (Olson and Gouaux, 2005), the tertiary structure model of VVH was 
constructed by using the SWISS-MODEL Workspace (Arnold et al., 2006). The model 
revealed that two domains were connected linearly and the C-terminal leucine was located 5 
close to the joint of the domains (Miyoshi et al., unpublished). This suggests that mutation of 
the N- or C-terminus of the lectin-like domain may result in inactivation of VVH because of 
change of the linear arrangement of the two domains. Kashimoto et al. (2010) recently found 
that mutation of Phe314 located near to the joint of the domains caused remarkable reduction 
of the cytolytic activity. However, the mutated toxin was found to bind sufficiently to the 10 
membrane. In the present study, several mutated toxins were prepared by using the cell-free 
translation system, and their hemolytic activities and cholesterol-binding abilities were 
compared. 
 
2. Materials and methods 15 
 
2.1. Bacterial strain and growth 
V. vulnificus strain CDC B3547 isolated from human leg ulcer was used in the present 
study. The bacterium was cultivated overnight at 37 oC in Luria-Bertani broth (1 % trypton, 
0.5 % yeast extract, 3.0 % NaCl, pH 7.5) with shaking. 20 
 
2.2. Toxin production by using the cell-free system 
As described by Senoh et al. (2008), the wild type or mutated toxin was produced with 
the rapid translation system (Roche Diagnostics, Mannheim, Germany) using the polymerase 
chain reaction (PCR)-amplified liner DNA fragments. To prepare the DNA fragments, in the 25 
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first PCR, an appropriate primer set carrying the 20 or 21 bp overlap region for the second 
PCR was designed from the nucleotide sequence of vvhA or vvhB of strain CDC B3547 
(GenBank accession number, AB124803). The bacterial genomic DNA extracted was 
heat-treated at 94 oC for 2 min, and the PCR using KOD-Plus DNA polymerase (Toyobo, 
Osaka, Japan) was carried out for 30 cycles as following: 1 min denaturation at 94 oC, 1 min 5 
annealing at an appropriate temperature, 2-3 min extension at 68 oC. 
In the second PCR, the sequences for T7 promoter and His6-Tag were added to the 
upstream, and the sequence for the T7 terminator was added to the down stream. The product 
of the first PCR was mixed with the RTS E. coli Linear Template Generation Set and His6-tag, 
and the admixture was subjected to the second PCR. After denaturation at 94 oC for 4 min, the 10 
reaction was carried out for 30 cycles as following: 1 min denaturation at 94 oC, 1 min 
annealing at 60 oC, and 2-3 min extension at 68 oC. 
Thereafter, the final cell-free translation was performed using the products of the second 
PCR as the linear template DNAs. The amplified DNA fragments corresponding to vvhA (1.0 
µg) and vvhB (0.5 µg) were mixed with the RTS 100 Escherichia coli HY Kit, and the 15 
translation was carried out at 25 oC for 6 hr according to the manufacture's manual. 
 For Western blotting, the crude toxin preparation was applied to a Phenyl-Sepharose HP 
5/5 column, and the toxin was partially purified as described (Senoh et al., 2008). The toxin 
thus prepared was treated at 100 oC for 5 min with an equal volume of the mixture of 2 % 
SDS and 5 % 2-mercaptoethanol (SDS-ME). An aliquot of the heat-treated sample was 20 
subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on the PhastSystem using 
a PhastGel Gradient 10-15 (GE Healthcare, Buckinghamshire, England), and the proteins 
were transferred to a polyvinylidene difluoride membrane. Thereafter, the toxin was detected 
with the rabbit IgG antibody against VVH purified from strain CDC B3547 (Oh et al., 1993) 
and the anti-rabbit IgG antibody conjugated with horseradish peroxidase (Cosmo-Bio, Tokyo, 25 
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Japan), and the density of the protein band detected was analyzed by using NIH Image 
version 2.1. 
 
2.3. Hemolytic activity 
The hemolytic activity was assayed according to the method of Shinoda et al. (1985) 5 
with some modifications. The toxin preparation (50 µl) was diluted serially with 20 mM 
Tris-HCl buffer (pH 7.5) containing 0.9 % NaCl and 0.01 % bovine serum albumin (TBS), 
and each of the toxin samples was allowed to act on 50 µl of 1 % sheep erythrocytes 
suspended into TBS at 37 oC. At 2 hr-incubation, the reaction was terminated by the addition 
of 0.4 ml of ice-cold TBS, and the supernatants were collected after centrifugation at 1000 x g 10 
for 5 min. Thereafter, the amount of hemoglobin liberated from the disrupted erythrocytes 
was quantified by measuring absorbance at 540 nm, and the amount of the toxin causing 50 % 
hemolysis was determined, and then, the relative activity of each mutated toxin was 
estimated. 
 15 
2.4. Binding to cholesterol particles 
The toxin preparation (10 µl) was allowed to act on cholesterol (1 to 10 µg in 1 µl of 
ethanol) in a total of 0.1 ml of TBS for 30 min at 0 or 37 oC. Thereafter, the cholesterol 
particles were collected by centrifugation (12000 x g for 5 min), rinsed twice with TBS and 
dissolved in an equal volume of SDS-ME by incubation at 37 oC for 30 min. An aliquot of the 20 
sample thus prepared was subjected to SDS-PAGE on the PhastSystem using a PhastGel 
Gradient 10-15, and the toxin was detected by Western blotting. 
 
2.5. Binding to erythrocyte membranes 
The resealed ghosts of sheep erythrocytes were prepared as reported by Funder and Wieth 25 
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(1976) and suspended into KRT buffer (128 mM NaCl, 5.1 mM KCl, 1.34 mM MgSO4, 2.7 
mM CaCl2, 10 mM Tris-HCl, pH 7.5) at a concentration of 8 %. The resealed ghosts (50 µl) 
thus prepared was mixed with the toxin preparation (50 µl) and incubated at 37 oC for 2 hr. 
Thereafter, the resealed ghosts were collected, and the toxin associated with the ghost was 
detected by SDS-PAGE followed by Western blotting. 5 
 
3. Results 
 
3-1. Hemolytic activities of mutated toxins 
Senoh et al. (2008) documented the sufficient hemolytic activity of the wild type toxin 10 
(sVVH) produced by using the cell-free translation system. In the present study, we prepared 
the cytolysin domain (Gln1 to Ala318) by using the same system and measured its hemolytic 
activity in the presence or absence of the lectin-like domain (His319 to Leu415). However, no 
hemolytic activity was observed even in the presence of the lectin-like domain, suggesting 
that the toxin must be produced as a single polypeptide to show the hemolytic activity. Next, 15 
we tested effect of the addition of amino acid residues to the N-terminus of the lectin-like 
domain. The hemolytic activity was reduced to 30 % by insertion of glycine-alanine between 
Ala318 and His319 and abolished completely by insertion of six glycine residues. Theses 
findings indicate that the direct connection of two domains is crucial to cause hemolysis. 
The tertiary structure model reveled that the C-terminus of the lectin-like domain (Leu451) 20 
was located close to the joint of two domains. Therefore, it was considered that the mutation 
of the C-terminus might affect the hemolytic activity. As shown in Table 1, the activity was 
reduced to less than 20 % by deletion of the C-terminal leucine (CΔ1). The preparation of the 
CΔ2 mutant was found to have no hemolytic activity; however, the Western blotting analysis 
indicated that this preparation contained the undetectable amount of the mutated toxin (data 25 
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not shown). Next, we tested effect of the addition of a residue to the C-terminus (Table 1). 
Although addition of leucine (VVH-L) or phenylalanine (VVH-F) gave a little impact in the 
hemolytic activity, addition of aspartic acid (VVH-D) or lysin (VVH-K) caused significant 
reduction of the activity. In addition, we examined whether substitution of Leu451 also causes 
inactivation of the toxin (Table 1). The toxin substituted to isoleucine (L451I) showed the 5 
partial hemolytic activity; however, substitution to aspartic acid (L451D) or lysin (L451K) 
resulted in drastic decrease in the activity. In contrast, change of Lys450 elicited less effect on 
the hemolytic activity (Table 1). 
The wild type and mutated toxins were partially purified by using a Phenyl-Sepharose HP 
5/5 column (Senoh et al., 2008) and subjected to SDS-PAGE followed by Western blotting. 10 
The results demonstrated that any mutation did not affect the translation process because the 
comparative amounts of the mutated toxins could be detected (data not shown). Therefore, it 
is concluded that the C-terminus leucine in the lectin-like domain is important for the 
hemolytic activity. 
 15 
3-2. Binding of mutated toxins to cholesterol 
In the first step of hemolysis, VVH binds to cholesterol in a temperature-independent 
manner (Shinoda et al., 1985). Since the lectin-like domain alone can mediate this first step 
(Senoh et al., 2008), it was speculated that the mutation of the C-terminus did not affect the 
ability to bind to cholesterol. The wild type or mutated toxin was allowed to act at 0 or 37 oC 20 
on cholesterol particles (10 µg at 0 oC, 1 or 5 µg at 37 oC), and the toxin associated with 
cholesterol particles was detected by Western blotting. When incubated at 37 oC, both the wild 
type and mutated toxins revealed the sufficient binding to the cholesterol particles (data not 
shown). Additionally, two inactive mutants (CΔ1 and L451K), as well as an active one 
(VVH-L), could associate with cholesterol particles even when the reaction was carried out at 25 
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0 oC (Fig. 1A). We also examined the binding of the mutated toxin, L451K, to erythrocyte 
membranes. The Western blotting analysis of the resealed erythrocyte ghosts incubated with 
sVVH or L451K demonstrated the comparative binding of the toxin to the membranes (Fig. 
1B). These findings indicate that the mutated toxins have the sufficient ability to bind to 
cholesterol. Therefore, the second process for hemolysis, assembly of the toxin molecules, 5 
may be blocked in the mutated toxins. However, the follow-up experiments to determine 
dissociation constants or to compare the affinity of the toxins to cholesterol. 
 
3-3. Hemolysis in the presence of the mutated toxin 
The native PAGE is a useful method to detect the toxin oligomer formed by 10 
auto-assembly on erythrocyte membrane or cholesterol particles (Miyoshi et al., 2004). 
However, when the cholesterol particles incubated with sVVH were subjected to native PAGE, 
no protein band corresponding to the toxin oligomer could be detected (data not shown). Next, 
we carried out modified SDS-PAGE of cholesterol particles incubated with sVVH, in which 
the heat-treatment of the sample with SDS-ME was omitted to protect dissociation of the 15 
toxin oligomer to the monomer. However, the oligomer of sVVH could not be detected in the 
modified SDS-PAGE analysis (data not shown). Although it is not known why the toxin 
oligomer was not detected, the N-terminal His6-Tag in sVVH might disturb the mobility of the 
toxin oligomer in native PAGE or modified SDS-PAGE. 
We also tested whether the presence of the excess amounts of the mutated toxin could 20 
interfere the hemolysis elicited by the wild type toxin. The sVVH was mixed with CΔ1 or 
L451K at the molar ratio of 1:0 to 1:5, and the hemolytic activity of each mixture was 
compared. As shown in Fig. 2, either mutated toxin showed no effect on the hemolytic activity. 
This suggests that the mutated toxin could not interact with sVVH on the erythrocyte 
membrane. 25 
 10 
 
4. Discussion 
 
VVH is a single polypeptide toxin consisting of two functional domains, the cytolysin 
domain (Gln1 to Arg318) and lectin-like domain (His319 to Leu451) (Olson and Gouaux, 2005). 5 
This toxin is known to cause hemolysis through several steps (Miyoshi et al., 1993). Namely, 
in the first step, the lectin-like domain binds specifically to cholesterol in a 
temperature-independent manner, and in the second step, the toxin forms a hollow oligomer 
through autoassembly in a temperature-dependent manner. Senoh et al. (2008) recently 
demonstrated that Thr438 in the lectin-like domain was related to the binding to cholesterol. 10 
On the other hand, Kashimoto et al. (2010) reported that mutation of Phe314, which is in the 
cytolysin domain but is located near to the joint of two domains, elicited elimination of the 
ability to form the toxin oligomer. The present study showed that mutation of Leu451, of which 
location is also close to the joint of the domains, caused inactivation of VVH without 
significant reduction of the ability to bind to cholesterol particles and sheep erythrocyte 15 
membranes. In addition, VVH had lost the hemolytic activity by insertion of residues to the 
N-terminus of the lectin-like domain. Although significant change in the tertiary structure 
model was not observed, these mutations might result in blockage of formation of the toxin 
oligomer through autoassembly. 
V. vulnificus is a ubiquitous microorganism in the estuarine and marine environments 20 
(Janda et al., 1988; Chakraborty et al., 1997) whereas an etiological agent causing fatal 
septicemia in humans by eating contaminated seafood (Strom and Paranjpye, 2000; Miyoshi 
2006). VVH is commonly produced by V. vulnificus as a major exocellular toxin (Shinoda et 
al., 1985; Miyoshi et al., 1993), and its structure gene has been used as a characteristic gene to 
identify the bacterium (Hill et al., 1991; Senoh et al., 2005). In our knowledge, VVH shows 25 
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no immunological cross-reactivity to other bacterial hemolytic/cytolytic toxins including 
those produced by human pathogenic Vibrio species. Therefore, the development of the 
immunological assay method targeting VVH is useful for the clinical diagnosis of V. 
vulnificus infection and screening of the seafood or environmental samples contaminated with 
the bacterium. The mutated toxins prepared in this study may be strong candidates for the 5 
non-toxic and safety antigens/toxoids to produce the specific antibody to the toxin. 
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Table 1. Hemolytic activities of toxins produced by using the cell-free 
translation system 
Toxin Hemolytic activity 
(%) 
Wild type toxin sVVH 100 
Mutated toxin   
Deletion CΔ1 16.7 + 3.3 
 CΔ2 ND* 
Addition VVH-L 126 + 6.7 
 VVH-F 118 + 11 
 VVH-D 23.7 + 3.9 
 VVH-K 24.1 + 4.4 
Substitution (Leu451) L451I 60.4 + 5.1 
 L451F 16.6 + 4.7 
 L451D 3.2 + 1.1 
 L451K 0.9 + 0.7 
Substitution (Lys450) K450R 102 + 2.5 
 K450H 90.2 + 4.5 
 K450E 62.2 + 6.4 
 K450L 45.6 + 5.0 
*  The activity could not be determined because of the sufficient 
amount of the toxin was not produced. 
 
5 
 15 
Figure legends 
 
Fig. 1.	 The cholesterol-binding abilities of the wild type and mutated toxins. (A) Each 
of the toxin preparation (10 µL) was allowed to act on cholesterol (10 µg) in a total of 0.1 ml 
of TBS at 0 oC for 30 min. Thereafter, the toxin bound to cholesterol particles was collected 5 
and detected by Western blotting. (B) The resealed ghosts (50 µl) was mixed with the toxin 
preparation (50 µl) and incubated at 37 oC for 2 hr. Thereafter, the resealed ghosts were 
collected, and the toxin associated with the ghost was detected by Western blotting. The data 
indicated are representative results of three experiments. 
 10 
Fig. 2.	 Effect of the mutated toxin on the hemolysis caused by the wild-type toxin. The 
wild toxin was mixed with the mutated toxin (CΔ1 or L451K) at the molar ratio 1:0 to 1:5, 
and the hemolytic activity of each mixture was measured with sheep erythrocytes at 37 oC for 
2 hr. The data indicated are the means and standard deviations of three experiments. 
 15 
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